WO2009157938A1 - Antagonistes de récepteur d’adénosine a2b pour traiter le cancer - Google Patents

Antagonistes de récepteur d’adénosine a2b pour traiter le cancer Download PDF

Info

Publication number
WO2009157938A1
WO2009157938A1 PCT/US2008/068423 US2008068423W WO2009157938A1 WO 2009157938 A1 WO2009157938 A1 WO 2009157938A1 US 2008068423 W US2008068423 W US 2008068423W WO 2009157938 A1 WO2009157938 A1 WO 2009157938A1
Authority
WO
WIPO (PCT)
Prior art keywords
dione
cancer
trihydropurine
formula
dipropyl
Prior art date
Application number
PCT/US2008/068423
Other languages
English (en)
Inventor
Rao Kalla
Thao Perry
Elfatih Elzein
Vaibhav Vardhedkar
Xiaofen Li
Prabha Ibrahim
Venkata Palle
Dengming Xiao
Jeff Zablocki
Hongyan Zhong
Dewan Zeng
Original Assignee
Cv Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cv Therapeutics, Inc. filed Critical Cv Therapeutics, Inc.
Priority to PCT/US2008/068423 priority Critical patent/WO2009157938A1/fr
Publication of WO2009157938A1 publication Critical patent/WO2009157938A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A61K31/52—Purines, e.g. adenine
    • A61K31/522—Purines, e.g. adenine having oxo groups directly attached to the heterocyclic ring, e.g. hypoxanthine, guanine, acyclovir
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Abstract

La présente invention concerne des antagonistes de récepteur d’adénosine A2B ayant la structure de formule (I) ou de formule (II) pour traiter le cancer.
PCT/US2008/068423 2008-06-26 2008-06-26 Antagonistes de récepteur d’adénosine a2b pour traiter le cancer WO2009157938A1 (fr)

Priority Applications (1)

Application Number Priority Date Filing Date Title
PCT/US2008/068423 WO2009157938A1 (fr) 2008-06-26 2008-06-26 Antagonistes de récepteur d’adénosine a2b pour traiter le cancer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/US2008/068423 WO2009157938A1 (fr) 2008-06-26 2008-06-26 Antagonistes de récepteur d’adénosine a2b pour traiter le cancer

Publications (1)

Publication Number Publication Date
WO2009157938A1 true WO2009157938A1 (fr) 2009-12-30

Family

ID=40428041

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2008/068423 WO2009157938A1 (fr) 2008-06-26 2008-06-26 Antagonistes de récepteur d’adénosine a2b pour traiter le cancer

Country Status (1)

Country Link
WO (1) WO2009157938A1 (fr)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143229A (zh) * 2013-03-15 2015-12-09 海德拉生物科学有限公司 取代的黄嘌呤及其使用方法
WO2019135259A1 (fr) 2018-01-04 2019-07-11 Impetis Biosciences Ltd. Composés tricycliques, compositions et leurs applications médicinales
CN112851675A (zh) * 2021-01-15 2021-05-28 北京益民药业有限公司 一种8-氯茶碱的粒径控制方法
US11124515B2 (en) 2018-03-05 2021-09-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
US11807623B2 (en) 2017-11-30 2023-11-07 Arrakis Therapeutics, Inc. Nucleic acid-binding photoprobes and uses thereof
US11981679B2 (en) 2018-01-04 2024-05-14 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042214A2 (fr) * 2001-11-09 2003-05-22 Cv Therapeutics, Inc. Antagonistes de recepteur d'adenosine a¿2b?
WO2004106337A1 (fr) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Derives de xanthine servant d'antagonistes du recepteur de l'adenosine a2b
WO2006138376A1 (fr) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrogues d'antagonistes de recepteur d'adenosine a2b
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
WO2009011893A2 (fr) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Traitements de troubles prolifératifs des lymphocytes b

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2003042214A2 (fr) * 2001-11-09 2003-05-22 Cv Therapeutics, Inc. Antagonistes de recepteur d'adenosine a¿2b?
US20080194593A1 (en) * 2001-11-09 2008-08-14 Rao Kalla A2b adenosine receptor antagonists
WO2004106337A1 (fr) * 2003-05-06 2004-12-09 Cv Therapeutics, Inc. Derives de xanthine servant d'antagonistes du recepteur de l'adenosine a2b
WO2006138376A1 (fr) * 2005-06-16 2006-12-28 Cv Therapeutics, Inc. Prodrogues d'antagonistes de recepteur d'adenosine a2b
WO2009011893A2 (fr) * 2007-07-17 2009-01-22 Combinatorx, Incorporated Traitements de troubles prolifératifs des lymphocytes b

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
KALLA RAO V ET AL: "Progress in the discovery of selective, high affinity A(2B) adenosine receptor antagonists as clinical candidates", PURINERGIC SIGNALLING, vol. 5, no. 1, 21 June 2008 (2008-06-21), pages 21 - 29, XP002519562, ISSN: 1573-9538 *
PRESS N J ET AL: "Therapeutic potential of adenosine receptor antagonists and agonists", EXPERT OPINION ON THERAPEUTIC PATENTS 200708 GB, vol. 17, no. 8, August 2007 (2007-08-01), pages 979 - 991, XP002519561, ISSN: 1354-3776 *

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105143229A (zh) * 2013-03-15 2015-12-09 海德拉生物科学有限公司 取代的黄嘌呤及其使用方法
US9969736B2 (en) 2013-03-15 2018-05-15 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
US10399982B2 (en) 2013-03-15 2019-09-03 Hydra Biosciences, Inc. Substituted xanthines and methods of use thereof
US11208409B2 (en) 2013-03-15 2021-12-28 Hydra Biosciences, Llc Substituted xanthines and methods of use thereof
US11958854B2 (en) 2013-03-15 2024-04-16 Hydra Biosciences, Llc Substituted xanthines and methods of use thereof
US11807623B2 (en) 2017-11-30 2023-11-07 Arrakis Therapeutics, Inc. Nucleic acid-binding photoprobes and uses thereof
WO2019135259A1 (fr) 2018-01-04 2019-07-11 Impetis Biosciences Ltd. Composés tricycliques, compositions et leurs applications médicinales
US11407758B2 (en) 2018-01-04 2022-08-09 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
US11981679B2 (en) 2018-01-04 2024-05-14 Impetis Biosciences Ltd. Tricyclic compounds, compositions and medicinal applications thereof
US11124515B2 (en) 2018-03-05 2021-09-21 Teon Therapeutics, Inc. Adenosine receptor antagonists and uses thereof
CN112851675A (zh) * 2021-01-15 2021-05-28 北京益民药业有限公司 一种8-氯茶碱的粒径控制方法

Similar Documents

Publication Publication Date Title
US6977300B2 (en) A2B adenosine receptor antagonists
US7741331B2 (en) A2B adenosine receptor antagonists
KR100937620B1 (ko) Ａ２ｂ 아데노신 수용체 길항제
US20080194593A1 (en) A2b adenosine receptor antagonists
AU2002359365A1 (en) A2B adenosine receptor antagonists
US20090137802A1 (en) A2b adenosine receptor antagonists
US20080318983A1 (en) A2b adenosine receptor antagonists
US7304070B2 (en) A2B adenosine receptor antagonists
AU2003249604B2 (en) A2B adenosine receptor antagonists
WO2009157938A1 (fr) Antagonistes de récepteur d’adénosine a2b pour traiter le cancer
WO2009088518A1 (fr) Antagonistes du récepteur d'adénosine a2b pour le traitement du cancer
RU2318825C2 (ru) Производные ксантина в качестве антагонистов a2b аденозинового рецептора
AU2011224104B2 (en) A2B adenosine receptor antagonists
KR20060055453A (ko) Ａ2ｂ 아데노신 수용체 길항제로서의 크산틴 유도체
NZ573577A (en) Xanthine derivatives as A2B adenosine receptor antagonists suitable for treating conditions such as asthma and diarrhoea

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 08781042

Country of ref document: EP

Kind code of ref document: A1

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 08781042

Country of ref document: EP

Kind code of ref document: A1